B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
B7-H3
CD276
antibody
cancer immunotherapy
immune checkpoint
Journal
International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
10
2019
accepted:
05
02
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
11
11
2021
Statut:
epublish
Résumé
B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may be a promising target for cancer treatment. B7-H3 protein was demonstrated to be expressed in several kinds of tumor tissues including non-small-cell lung cancer (NSCLC) and prostate cancer. Its expression is highly associated with undesirable treatment outcomes and survival time, due to function of the immune checkpoint molecule. It was classified as either a co-stimulatory molecule for T cell activation or the nonimmunological role of regulating signaling pathways. Although there is still no agreed conclusion on the function of B7-H3, it may be a valuable target for cancer therapy. This review aims to provide a comprehensive, up-to-date summary of the advances in B7-H3 targeting approaches in cancer therapy. Although several challenges remain, B7-H3 offers a new therapeutic target with increased efficacy and less toxicity in future cancer treatment.
Identifiants
pubmed: 32398947
doi: 10.7150/ijbs.41105
pii: ijbsv16p1767
pmc: PMC7211166
doi:
Substances chimiques
B7 Antigens
0
CD276 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1767-1773Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Chem Commun (Camb). 2019 Nov 26;55(95):14255-14258
pubmed: 31657388
Cancer Invest. 2014 Jul;32(6):262-71
pubmed: 24787022
Int J Mol Med. 2013 Feb;31(2):283-91
pubmed: 23242015
FEBS Lett. 2015 Aug 4;589(17):2248-56
pubmed: 26149216
Mol Ther Oncolytics. 2019 Jul 23;14:279-287
pubmed: 31485480
Oncol Rep. 2007 Sep;18(3):745-8
pubmed: 17671729
Cancer Immunol Immunother. 2018 May;67(5):805-814
pubmed: 29484464
Onco Targets Ther. 2017 Nov 13;10:5417-5424
pubmed: 29180874
Cancer Cell Int. 2015 Apr 21;15:45
pubmed: 25908926
BioDrugs. 2020 Apr;34(2):111-119
pubmed: 31916225
Nat Rev Clin Oncol. 2017 Apr;14(4):203-220
pubmed: 27805626
Oncol Lett. 2017 Nov;14(5):6177-6183
pubmed: 29113264
Nat Immunol. 2003 Sep;4(9):899-906
pubmed: 12925852
J Surg Res. 2014 May 15;188(2):396-403
pubmed: 24630518
Front Pharmacol. 2019 Jun 06;10:609
pubmed: 31244654
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Oncol Lett. 2013 Mar;5(3):805-812
pubmed: 23426281
Oncogene. 2019 Jan;38(1):88-102
pubmed: 30082909
Eur J Immunol. 2009 Jul;39(7):1754-64
pubmed: 19544488
Oncol Rep. 2017 Oct;38(4):2426-2434
pubmed: 28765941
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
J Immunol. 2010 Sep 15;185(6):3677-84
pubmed: 20696859
Bioorg Med Chem Lett. 2016 Oct 15;26(20):5069-5072
pubmed: 27599744
Med Oncol. 2014 Dec;31(12):349
pubmed: 25416051
Oncotarget. 2016 Apr 26;7(17):24888-98
pubmed: 27058890
Sci Rep. 2016 Jun 08;6:27528
pubmed: 27273624
Clin Cancer Res. 2018 Jun 1;24(11):2653-2664
pubmed: 29530936
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
Cancer Res. 2001 May 15;61(10):4048-54
pubmed: 11358824
Mol Med Rep. 2013 Jan;7(1):134-8
pubmed: 23128494
Curr Pharm Biotechnol. 2016;17(15):1324-1332
pubmed: 27758688
Int J Clin Exp Pathol. 2015 Nov 01;8(11):13987-95
pubmed: 26823710
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Oncotarget. 2016 Feb 9;7(6):6891-901
pubmed: 26771843
Oncol Lett. 2017 Dec;14(6):7185-7190
pubmed: 29344150
J Biol Chem. 2015 Dec 11;290(50):30018-29
pubmed: 26487718
Am J Transl Res. 2017 Mar 15;9(3):1369-1380
pubmed: 28386362
BMC Cancer. 2009 Dec 26;9:463
pubmed: 20035626
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Immunol. 2012 Jul 1;189(1):347-55
pubmed: 22661093
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
Mol Cancer Ther. 2011 Jun;10(6):960-71
pubmed: 21518725
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Int J Biol Sci. 2012;8(10):1420-30
pubmed: 23197939
Int J Biol Sci. 2020 Jan 1;16(4):568-582
pubmed: 32025206
J Gastrointest Surg. 2006 May;10(5):635-45
pubmed: 16713537
J Biol Chem. 2016 Feb 19;291(8):4048-57
pubmed: 26702052
Tumour Biol. 2016 Jul;37(7):9465-72
pubmed: 26787540
Sci Rep. 2019 Apr 9;9(1):5839
pubmed: 30967582
Pigment Cell Melanoma Res. 2017 Sep;30(5):467-476
pubmed: 28513992
Oncotarget. 2016 May 17;7(20):29480-91
pubmed: 27121051
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13057-62
pubmed: 26438868
Curr Med Chem. 2019 Jun 18;:
pubmed: 31250752
Clin Cancer Res. 2012 Jul 15;18(14):3834-45
pubmed: 22615450